Aralez Pharmaceuticals Inc (TSE:ARZ)’s share price traded up 4.1% on Thursday . The company traded as high as C$1.51 and last traded at C$1.51. 5,000 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 37,356 shares. The stock had previously closed at C$1.45.

Separately, Chardan Capital reaffirmed a “buy” rating on shares of Aralez Pharmaceuticals in a research note on Wednesday, May 17th.

The stock’s market capitalization is $98.27 million. The stock’s 50 day moving average is $1.47 and its 200 day moving average is $2.26.

In related news, Director Arthur S. Kirsch purchased 50,000 shares of the firm’s stock in a transaction on Wednesday, June 14th. The stock was purchased at an average cost of C$1.17 per share, for a total transaction of C$58,500.00.

TRADEMARK VIOLATION WARNING: “Aralez Pharmaceuticals Inc (ARZ) Trading 4.1% Higher” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at

Aralez Pharmaceuticals Company Profile

Aralez Pharmaceuticals Inc operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It offers Yosprala for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events; Toprol-XL, a cardioselective beta-blocker indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Zontivity for the reduction of thrombotic cardiovascular events in patients; Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; and Soriatane for the treatment of severe psoriasis and other disorders of keratinization.

Receive News & Stock Ratings for Aralez Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.